M. Naveed Shaik

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Jörge E. Cortes, Florian H. Heidel, Andrzej Hellmann et al. · Leukemia · 2018 · 474 citations · Full text

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Keith T. Flaherty, Patricia LoRusso, Angela DeMichele et al. · Clinical Cancer Research · 2011 · 359 citations

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

John P. Leonard, Ann S. LaCasce, Mitchell R. Smith et al. · Blood · 2012 · 291 citations · Full text

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

Gary K. Schwartz, P. LoRusso, Mark A. Dickson et al. · British Journal of Cancer · 2011 · 259 citations · Full text

A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014

Wells A. Messersmith, Geoffrey I. Shapiro, James M. Cleary et al. · Clinical Cancer Research · 2014 · 214 citations · Full text